Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Core Points - Artelo Biosciences, Inc. has announced the pricing of its public offering of 441,210 shares of common stock at $4.40 per share and pre-funded warrants at $4.399 per warrant, aiming for gross proceeds of approximately $2.0 million [1] - The offering is managed by R.F. Lafferty & Co., Inc. and is conducted under a "shelf" registration statement filed with the SEC [2] - The offering is expected to close on October 1, 2025, pending customary closing conditions [1] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and dermatologic issues [6] - The company has a diversified pipeline addressing significant unmet medical needs, including anorexia, anxiety, and inflammation [6] - Artelo is led by an experienced executive team and collaborates with world-class researchers and digital-asset technology partners to maximize stakeholder value [6]